Trial Profile

A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KNX 100 (Primary)
Indications Substance-related disorders
Focus Adverse reactions; First in man
Acronyms KTX101
Sponsors Kinoxis Therapeutics

Most Recent Events

11 Dec 2023 Status changed from recruiting to completed.
13 Feb 2023 Time frame changed to From Time of Consent to Follow Up Visit (38 days). Eligibility criteria changed to 18-55 years. Planned number of patients also increased.
13 Feb 2023 Planned number of patients changed from 40 to 64.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com